Treatment of ST Elevation Myocardial Infarction from Fibrinolysis to Primary PCI: In Terms of Risks and Benefits

References (118)

1. 1 Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation [DOI]
2. 2 Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction [DOI]
3. 3 Abciximab Facilitates the Rate and Extent of Thrombolysis [DOI]
4. 4 Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials [DOI]
5. 5 Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion [DOI]
6. 6 Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase [DOI]
7. 7 Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction [DOI]
8. 8 Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction [DOI]
9. 9 More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction [DOI]
10. 10 TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction [DOI]
11. 11 Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. [DOI]
12. 12 Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. [DOI]
13. 13 Having of mortality at 1 year by domiciliary thrombolysis in the grampian region early anistreplase trial (GREAT) [DOI]
14. 14 A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction [DOI]
15. 15 A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction [DOI]
16. 16 Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. [DOI]
17. 17 Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study 11This study was supported by grants from the Norwegian Council on Cardiovascular Diseases, Oslo, Norway and Pharmacia AB, Stockholm, Sweden. [DOI]
18. 18 Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis [DOI]
19. 19 Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS II) [DOI]
20. 20 Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial [DOI]
21. 21 Randomized Double-Blind Comparison of Two Doses of Hirulog With Heparin as Adjunctive Therapy to Streptokinase to Promote Early Patency of the Infarct-Related Artery in Acute Myocardial Infarction [DOI]
22. 22 Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrinolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial [DOI]
23. 23 Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy [DOI]
24. 24 A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. [DOI]
25. 25 The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. [DOI]
26. 26 Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS) [DOI]
27. 27 Intravenous urokinase in acute myocardial infarction [DOI]
28. 28 Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction [DOI]
29. 29 Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) [DOI]
30. 30 Multicenter trial of intravenous Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) in acute myocardial infarction: Effects on infarct size and left, ventricular function [DOI]
31. 31 Comparison of Saruplase and Alteplase in Acute Myocardial Infarction [DOI]
32. 32 Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction [DOI]
33. 33 Results of high dose intravenous urokinase for acute myocardial infarction [DOI]
34. 34 A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction [DOI]
35. 35 The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty [DOI]
36. 36 Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. [DOI]
37. 37 Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. [DOI]
38. 38 Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction [DOI]
39. 39 A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group. [DOI]
40. 40 Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction [DOI]
41. 41 Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens [DOI]
42. 42 Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study [DOI]
43. 43 Effects of early high-dose streptokinase intravenously on left ventricular function in acute myocardial infarction [DOI]
44. 44 Catheterization/rescue angioplasty following thrombolysis (craft) study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase [DOI]
45. 45 Patency Trials With Reteplase (r-PA): What Do They Tell Us? [DOI]
46. 46 A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction [DOI]
47. 47 High-dose intravenous thrombolytic therapy in acute myocardial infarction: efficiency, tolerance, complications and influence on left ventricular performance.
48. 48 Intravenous Thrombolytic Treatment for Acute Myocardial Infarction [DOI]
49. 49 Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction. [DOI]
50. 50 Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction [DOI]
51. 51 Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes [DOI]
52. 52 Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials [DOI]
53. 53 Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients [DOI]
54. 54 Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial [DOI]
55. 55 Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial [DOI]
56. 56 Relationship Between Time of Day, Day of Week, Timeliness of Reperfusion, and In-Hospital Mortality for Patients With Acute ST-Segment Elevation Myocardial Infarction [DOI]
57. 57 Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting [DOI]
58. 58 Comparison of Thrombolysis Followed by Broad Use of Percutaneous Coronary Intervention With Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Acute Myocardial Infarction [DOI]
59. 59 A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study [DOI]
60. 60 Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study) [DOI]
61. 61 Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial [DOI]
62. 62 TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction [DOI]
63. 63 Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. [DOI]
64. 64 Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial [DOI]
65. 65 Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA [DOI]
66. 66 Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 [DOI]
67. 67 Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) [DOI]
68. 68 Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial Infarction [DOI]
69. 69 Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction [DOI]
70. 70 Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI–SK study [DOI]
71. 71 A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction [DOI]
72. 72 Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage [DOI]
73. 73 Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction [DOI]
74. 74 One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction [DOI]
75. 75 A Review of Available Fibrin‐Specific Thrombolytic Agents Used in Acute Myocardial Infarction [DOI]
76. 76 Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data [DOI]
77. 77 Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy [DOI]
78. 78 RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION [DOI]
79. 79 Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. [DOI]
80. 80 Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. [DOI]
81. 81 Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction [DOI]
82. 82 Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) [DOI]
83. 83 Relationship between blood flow to ischemic regions and extent of myocardial infarction. Serial measurement of blood flow to ischemic regions in dogs. [DOI]
84. 84 Regional myocardial blood flow during acute myocardial infarction in the conscious dog. [DOI]
85. 85 Evaluation of a Weight-Adjusted Single-Bolus Plasminogen Activator in Patients With Myocardial Infarction [DOI]
86. 86 Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction [DOI]
87. 87 A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. [DOI]
88. 88 Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction [DOI]
89. 89 High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial [DOI]
90. 90 Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction [DOI]
91. 91 An angiographic assessment of alteplase: Double-bolus and front-loaded infusion regimens in myocardial infarction [DOI]
92. 92 Impacto de la trombolisis y de la angioplastia primaria en pacientes con infarto agudo del miocardio tratados en centros hospitalarios terciarios [DOI]
93. 93 DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION [DOI]
94. 94 Effect of Intravenous Streptokinase as Compared with That of Tissue Plasminogen Activator on Left Ventricular Function after First Myocardial Infarction [DOI]
95. 95 A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. [DOI]
96. 96 Plasminogen activator italian multicenter study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-pa) with intravenous streptokinase in acute myocardial infarction [DOI]
97. 97 Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction [DOI]
98. 98 High-dose, brief intravenous streptokinase early in acute myocardial infarction [DOI]
99. 99 Anisoylated Plasminogen Streptokinase Activator Complex versus Streptokinase in Acute Myocardial Infarction [DOI]
100. 100 Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction [DOI]
101. 101 A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction [DOI]
102. 102 Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*
103. 103 Implementation of Guidelines Improves the Standard of Care [DOI]
104. 104 Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial [DOI]
105. 105 [Intracoronary administration of fibrinolysin in acute myocardial infarct].
106. 106 Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin [DOI]
107. 107 The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy.
108. 108 A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial Infarction [DOI]
109. 109 Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog [DOI]
110. 110 Comparison of the Efficacy of Reperfusion Therapies for Early Mortality From Acute Myocardial Infarction in Japan [DOI]
111. 111 Significant decrease of in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007 [DOI]
112. 112 A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary Angioplasty [DOI]
113. 113 Randomized, Double-Blind Study Comparing Saruplase With Streptokinase Therapy in Acute Myocardial Infarction: The COMPASS Equivalence Trial fn1fn1This study was supported by Grünenthal GmbH, the manufacturer of saruplase. [DOI]
114. 114 Initial experience withhirudin andstreptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trial [DOI]
115. 115 Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction [DOI]
116. 116 Do we reperfuse those in most need? Clinical characteristics of ST-elevation myocardial infarction patients receiving reperfusion therapy in the countrywide registry HELIOS.
117. 117 Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction.
118. 118 [A european multicenter and randomized study of APSAC versus streptokinase in myocardial infarction].

Cited by 0

No indexed citations yet.

Related research

• A Retrospective Observational Case Study to Assess the Safety and Feasibility of Percutaneous Dilatational Tracheostomy Performed by Trainees — shares topic coverage
• Drug-drug Interactions between Warfarin and Antimicrobials: A Systematic Review — shares topic coverage
• Retrospective Analysis of Cancer Cervix at Awal Bros Batam Hospital in 2020-2022 — shares topic coverage
• An Evaluation of the Sub Acute Toxicity and Haemostatic Effects of Leaves Extract of Achyranthes aspera in Mice and Albino Rats — shares topic coverage
• Predictors of Bleeding after Percutaneous Coronary Intervention — shares topic coverage